Serum PSA testing can identify men with clinically significant prostate cancer but exposes many more men to the diagnosis of indolent tumours. Benafif and colleagues have published the results of the BARCODE1 pilot study, in which they propose using germline single-nucleotide polymorphisms to identify men with a genetic risk of developing prostate cancer. Based on their preliminary findings, changing the current prostate cancer screening paradigm will be a challenge.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Catalona, W. J. et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N. Engl. J. Med. 324, 1156–1161 (1991).
Lane, J. A. et al. Active monitoring, radical prostatectomy, or radiotherapy for localized prostate cancer: study design and diagnostic baseline results of the ProtecT randomized phase 3 trial. Lancet Oncol. 15, 1109–1118 (2014).
Nordström, T. et al. Comparison between the four-kallikrein panel and prostate health index for predicting prostate cancer. Eur. Urol. 68, 139–146 (2015).
Grönberg, H. et al. Prostate cancer screening in men aged 50–69 years (STHLM3): a prospective population-based diagnostic study. Lancet Oncol. 16, 1667–1676 (2015).
Eklund, M. et al. MRI-targeted or standard biopsy in prostate cancer screening. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2100852 (2021).
Schumacher, F. R. et al. Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Nat. Genet. 50, 928–936 (2018).
Benafif, S. et al. The BARCODE1 Pilot: a feasibility study of using germline single nucleotide polymorphisms to target prostate cancer screening. BJU Int. https://doi.org/10.1111/BJU.15535 (2021).
Welch, H. G. & Albertsen, P. C. Reconsidering prostate cancer mortality – the future of PSA screening. N. Engl. J. Med. 382, 1557–1563 (2020).
Fenton, J. J. et al. Prostate-specific antigen-based screening for prostate cancer: evidence report and systematic review for the US Preventive Services Task Force. JAMA 319, 1914–1931 (2018).
Kovac, E. et al. Association of baseline prostate-specific antigen level with long-term diagnosis of clinically significant prostate cancer among patients aged 55 to 60 years: a secondary analysis of a cohort in the prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial. JAMA Netw. Open 3, e1919284 (2020).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing interests.
Rights and permissions
About this article
Cite this article
Albertsen, P.C. Prostate cancer screening: a new way forward or another false start?. Nat Rev Urol 18, 579–580 (2021). https://doi.org/10.1038/s41585-021-00513-w
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41585-021-00513-w
